---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-274491"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:32:02.348508+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Johnson & Johnson to acquire Abiomed for $380/share plus CVR; enterprise value ~$16.6B

## Summary
- Upfront cash $380/share + CVR up to $35/share; total implied value ~$415/share.
- Enterprise value ~$16.6B including cash acquired; deal expected to close by mid-2023.
- CVR milestones: net sales >$3.7B; FDA approval for Impella in STEMI; Class I guidelines.
- Transaction broadens JNJ MedTech cardiovascular portfolio; accretive to adjusted EPS in 2024.

## SEC filing metadata
- accession: 0001193125-22-274491
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/0001193125-22-274491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/d395813d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-274491
- JSON: https://secwatch.observer/filing/0001193125-22-274491.json
- Plain text: https://secwatch.observer/filing/0001193125-22-274491.txt

## Key facts
- Material Agreements
  JOHNSON & JOHNSON entered into Agreement and Plan of Merger with ABIOMED, Inc. valued at Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on (effective 2022-10-31).
  - Action: entry
  - Agreement: merger
  - Counterparty: ABIOMED, Inc.
  - Value: Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on
  - Effective: 2022-10-31
  source text: Item 1.01 Entry into a Material Definitive Agreement Agreement and Plan of Merger On October 31, 2022, Johnson & Johnson, a New Jersey corporation (“ Johnson & Johnson ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson (“ Merger Sub ”), and ABIOMED, Inc., a Delaware corporation (“ ABIOMED ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/0001193125-22-274491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.